Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan

NAOTAKA SHIMOZATO, TADASHI NAMISAKI, AKIHIRO OKANO, MASAYA OHANA, DAISUKE KINOSHITA, TOSHIHIKO KAWASAKI, YOSUKE AIHARA, TOSHIYA NAKATANI, HIROKI KINOSHITA, TATSUICHI ANN, KO SAITO, MOTOYUKI YOSHIDA and HITOSHI YOSHIJI
Anticancer Research January 2022, 42 (1) 173-183; DOI: https://doi.org/10.21873/anticanres.15471
NAOTAKA SHIMOZATO
1Department of Gastroenterology, Nara Medical University, Kashihara, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TADASHI NAMISAKI
1Department of Gastroenterology, Nara Medical University, Kashihara, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tadashin{at}naramed-u.ac.jp
AKIHIRO OKANO
2Department of Gastroenterology, Tenri Hospital, Tenri, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAYA OHANA
2Department of Gastroenterology, Tenri Hospital, Tenri, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DAISUKE KINOSHITA
3Department of Gastroenterology, Kindai University Nara Hospital, Ikoma, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOSHIHIKO KAWASAKI
3Department of Gastroenterology, Kindai University Nara Hospital, Ikoma, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSUKE AIHARA
4Department of Gastroenterology, Nara Prefecture General Medical Center, Nara, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOSHIYA NAKATANI
4Department of Gastroenterology, Nara Prefecture General Medical Center, Nara, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROKI KINOSHITA
5Gastroenterology, Bell Land General Hospital, Sakai, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TATSUICHI ANN
5Gastroenterology, Bell Land General Hospital, Sakai, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KO SAITO
6Department of Gastroenterology, Nara Prefecture Seiwa Medical Center, Sango, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MOTOYUKI YOSHIDA
6Department of Gastroenterology, Nara Prefecture Seiwa Medical Center, Sango, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HITOSHI YOSHIJI
1Department of Gastroenterology, Nara Medical University, Kashihara, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 42 no. 1 173-183
DOI 
https://doi.org/10.21873/anticanres.15471
PMID 
34969723

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received October 16, 2021
  • Revision received November 19, 2021
  • Accepted November 25, 2021
  • Published online December 29, 2021.

Copyright & Usage 
Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Author Information

  1. NAOTAKA SHIMOZATO1,
  2. TADASHI NAMISAKI1⇑,
  3. AKIHIRO OKANO2,
  4. MASAYA OHANA2,
  5. DAISUKE KINOSHITA3,
  6. TOSHIHIKO KAWASAKI3,
  7. YOSUKE AIHARA4,
  8. TOSHIYA NAKATANI4,
  9. HIROKI KINOSHITA5,
  10. TATSUICHI ANN5,
  11. KO SAITO6,
  12. MOTOYUKI YOSHIDA6 and
  13. HITOSHI YOSHIJI1
  1. 1Department of Gastroenterology, Nara Medical University, Kashihara, Japan
  2. 2Department of Gastroenterology, Tenri Hospital, Tenri, Japan
  3. 3Department of Gastroenterology, Kindai University Nara Hospital, Ikoma, Japan
  4. 4Department of Gastroenterology, Nara Prefecture General Medical Center, Nara, Japan
  5. 5Gastroenterology, Bell Land General Hospital, Sakai, Japan
  6. 6Department of Gastroenterology, Nara Prefecture Seiwa Medical Center, Sango, Japan
  1. Correspondence to: Tadashi Namisaki, Department of Gastroenterology of Nara Medical University, 840 Shijo, Kashihara, Nara 634-0813, Japan. Tel: +81 744223051 (ext. 3415), Fax: +81 744247122, e-mail: tadashin{at}naramed-u.ac.jp
View Full Text

Statistics from Altmetric.com

Cited By...

  • 8 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 42, Issue 1
January 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan
NAOTAKA SHIMOZATO, TADASHI NAMISAKI, AKIHIRO OKANO, MASAYA OHANA, DAISUKE KINOSHITA, TOSHIHIKO KAWASAKI, YOSUKE AIHARA, TOSHIYA NAKATANI, HIROKI KINOSHITA, TATSUICHI ANN, KO SAITO, MOTOYUKI YOSHIDA, HITOSHI YOSHIJI
Anticancer Research Jan 2022, 42 (1) 173-183; DOI: 10.21873/anticanres.15471

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan
NAOTAKA SHIMOZATO, TADASHI NAMISAKI, AKIHIRO OKANO, MASAYA OHANA, DAISUKE KINOSHITA, TOSHIHIKO KAWASAKI, YOSUKE AIHARA, TOSHIYA NAKATANI, HIROKI KINOSHITA, TATSUICHI ANN, KO SAITO, MOTOYUKI YOSHIDA, HITOSHI YOSHIJI
Anticancer Research Jan 2022, 42 (1) 173-183; DOI: 10.21873/anticanres.15471
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Cost-effectiveness Analysis of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Intermediate-stage Hepatocellular Carcinoma: A Real-world Retrospective Study
  • Tranilast Inhibits TRPV2 and Suppresses Fibrosis Progression and Weight Gain in a NASH Model Mouse
  • Surgical Intervention After Lenvatinib Treatment in Patients With Advanced Hepatocellular Carcinoma
  • Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients
  • Impact of Post-progression Survival on Outcomes of Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Retrospective Cohort Study
  • Leaky Gut and Severe Adverse Events in Advanced Hepatocellular Carcinoma Treated With Lenvatinib
  • Google Scholar

More in this TOC Section

  • Real-world Delivery and Outcomes of Intravesical BCG for Non–muscle-invasive Bladder Cancer
  • Early Progressive Disease Predicts Poor Outcomes of Second-line VEGFR Tyrosine Kinase Inhibitor Therapy After First-line Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma
  • Evaluation of Quality Metrics for Dose Assessment in Field Overlap Regions of VMAT-Based Craniospinal Axis Irradiation
Show more Clinical Studies

Keywords

  • lenvatinib
  • tyrosine kinase inhibitor
  • Hepatocellular carcinoma
  • Child–Pugh
  • Adverse events
  • progression-free survival
  • objective response
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire